For Investors
Global Kinetics Corporation is a commercial-stage digital health company revolutionising the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments.
The company’s Parkinson’s KinetiGraph™ system (PKG® or Personal KinetiGraph™ in the USA) is a patient-friendly, algorithm-based system that records patients’ movements over the course of several days and creates data-driven reports that empowers more personalised treatment and management decisions—ultimately leading to a higher quality of life for patients.
The PKG® system is being used in clinics across the U.S., Europe and Asia Pacific, enabling better clinical outcomes and reducing health care costs across the Parkinson’s disease continuum. Global Kinetics Corporation continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure efficacy of new and advanced therapies for one of the world’s most widespread movement disorders.
| Name | Global Kinetics Corporation Limited (GKC) |
| Status | Privately-held Australian company |
| Industry/Sector | Digital health/Parkinson's disease and other movement disorders |
| Established | July 2007 in Melbourne, Australia |
| Locations | Australia (headquarters), USA and European Union |
| Personnel | 42 FTE (Australia 19, USA 7, European Union 12) |
| Financings | Five private rounds, all at progressively higher prices |
Treat to Target trial announcement
GKC has successfully secured funding from the high profile and leading international funder in Parkinson's - The Michael J. Fox Foundation as well as the Shake It Up Australia Foundation and Parkinson's Victoria, to support a global trial to evaluate the use of objective targets to guide the treatment and management of Parkinson's disease. Read press release here.